1 Min Read
Oct 17 (Reuters) - Regeneron Pharmaceuticals Inc and partner Teva Pharmaceutical Industries Ltd said the U.S. health regulator has placed a clinical hold on a mid-stage study of their experimental drug for chronic lower back pain.
The Food and Drug Administration (FDA) imposed the hold after observing a case of a type of joint inflammation in an advanced osteoarthritis patient, who was given a high dose of the drug, fasinumab.
Following the FDA decision, Regeneron has completed an unplanned interim review of data and has stopped dosing patients, the company said on Monday.
Fasinumab is also in development for use in osteoarthritis pain. (Reporting by Natalie Grover in Bengaluru; Editing by Anil D'Silva)